Ameriprise’s Inhibikase Therapeutics IKT Stock Holding History

Ameriprise’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,376,395	Closed	-$2.82M	–	4143
2025 Q4	$2.82M	Buy	+1,376,395	New	+$2.19M	﹤0.01%	2815

Other funds holding IKT

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ameriprise's IKT Position: Q1 2026 in Review

Ameriprise sold out of Inhibikase Therapeutics (IKT) in Q1 2026, closing a stake of 1,376,395 shares — an estimated $2.82M sold.

Ameriprise first reported a position in IKT in Q4 2025 and held it in 1 quarter. The position peaked at $2.82M in Q4 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

Ameriprise reported no remaining Inhibikase Therapeutics position as of Q1 2026 after selling out during the quarter.
Ameriprise sold 1,376,395 Inhibikase Therapeutics shares in Q1 2026, an estimated $2.82M.
Ameriprise first reported a position in Inhibikase Therapeutics in Q4 2025 and held it in 1 quarter.
Ameriprise's Inhibikase Therapeutics position peaked at $2.82M in Q4 2025.
104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.